VNDA
Vanda Pharmaceuticals Inc.
Biotechnology · Healthcare · United States
5.03
close · 2026-08-13
value
82
cheaper than peers82
quality
24
stronger fundamentals24
ranked against
Biotechnology (commercial)
value
quality
101 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 1.41× | 98 |
| price to book | 1.08× | 94 |
| forward P/E | 25.15× | 32 |
3 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 10.4% | 64 |
| operating margin | -126.3% | 40 |
| revenue growth | -3.9% | 26 |
| return on equity | -77.8% | 22 |
4 of 4 measures available
Facts
| market cap | $304M |
| free cash flow | -$86.7M |
| employees | 533 |
| first trade | 2006-04-12 |
| next earnings | 2026-08-05 |
| fundamentals updated | 2026-08-10 |